Analyzing Carlyle Secured Lending (NASDAQ:CGBD) & ReNeuron Group (OTCMKTS:RNUGF)

ReNeuron Group (OTCMKTS:RNUGF) and Carlyle Secured Lending (NASDAQ:CGBD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Valuation and Earnings

This table compares ReNeuron Group and Carlyle Secured Lending”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReNeuron Group	$640,000.00	0.10	-$6.52 million	N/A	N/A
Carlyle Secured Lending	$107.43 million	8.46	$92.28 million	$1.79	9.97

Carlyle Secured Lending has higher revenue and earnings than ReNeuron Group.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ReNeuron Group and Carlyle Secured Lending, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReNeuron Group	0	0	0	0	0.00
Carlyle Secured Lending	1	1	1	0	2.00

Carlyle Secured Lending has a consensus price target of $16.67, indicating a potential downside of 6.63%. Given Carlyle Secured Lending’s stronger consensus rating and higher probable upside, analysts plainly believe Carlyle Secured Lending is more favorable than ReNeuron Group.

Profitability

This table compares ReNeuron Group and Carlyle Secured Lending’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReNeuron Group	N/A	N/A	N/A
Carlyle Secured Lending	40.69%	12.60%	5.77%

Insider & Institutional Ownership

24.5% of Carlyle Secured Lending shares are held by institutional investors. 0.6% of Carlyle Secured Lending shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

ReNeuron Group has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, Carlyle Secured Lending has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.

Summary

Carlyle Secured Lending beats ReNeuron Group on 12 of the 12 factors compared between the two stocks.

About ReNeuron Group

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

About Carlyle Secured Lending

Carlyle Secured Lending, Inc. is business development company specializing in first lien debt, senior secured loans, second lien senior secured loan unsecured debt, mezzanine debt and investments in equities. It specializes in directly investing. It specializes in middle market. It targets healthcare and pharmaceutical, aerospace and defense, high tech industries, business services, software, beverage food and tobacco, hotel gamming and leisure, banking finance insurance and in real estate sector. The fund seeks to invest across United States of America, Luxembourg, Cayman Islands, Cyprus, and United Kingdom. It invests in companies with EBITDA between $25 million and $100 million.